Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Maurey, P. Henno, C. Delclaux, P. Bonnette, D. Israel-Biet, M. Levy (Paris, Suresnes, France). Role of endothelin-1 in endothelial dysfunction in cystic fibrosis. Eur Respir J 2007; 30: Suppl. 51, 340

Member's Comments

No comment yet.

Related content which might interest you: Endothelial dysfunction in cystic fibrosis: imbalance NOS/arginase? Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage Year: 2007 PP309 – Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis Source: ERS Lung Science Conference 2021 Year: 2021 Role of IL-11 in vascular function of pulmonary fibrosis patients Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-kappa B and endothelin-1 Source: Eur Respir J 2009; 34: 1329-1337 Year: 2009 Role of endothelin in lung fibrosis Source: Eur Respir Rev 2008; 17: 145-150 Year: 2008 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Imbalance between circulating endothelial cells and endothelial progenitors in idiopathic pulmonary fibrosis Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (2) 2101645; 10.1183/13993003.01645-2021 Year: 2021 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Primary pulmonary hypertension and endothelial dysfunction Source: Eur Respir J 2003; 22: Suppl. 45, 583s Year: 2003 Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration? Source: Eur Respir J, 56 (4) 2003167; 10.1183/13993003.03167-2020 Year: 2020 Epithelium involvement and remodeling of interstitium in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006 Arterial stiffness and endothelial dysfunction in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Premature vascular ageing in cystic fibrosis Source: Eur Respir J 2009; 34: 1217-1218 Year: 2009 Endogenous and nitrovasodilator-induced release of NO in the airways of end-stage cystic fibrosis patients Source: Eur Respir J 2010; 36: 682-683 Year: 2010 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Impairment of membranous and vascular components of pulmonary diffusion and plasma endothelin-1 in patients with liver cirrhosis with and without COPD Source: Annual Congress 2011 - COPD diagnosis Year: 2011 LSC - 2021 - Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis Year: 2021